

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
KRAUSE, ANDREAS ET AL.

ART UNIT: 1636
EXAMINER: DUNSTON,
JENNIFER A

INTERNATIONAL APPLICATION NO: PCT/EP03/09292

FILED: AUGUST 21, 2003

U.S. APPLICATION NO: 10/524399

35 USC §371 DATE: FEBRUARY 11, 2005

FOR: DIAGNOSIS OF CHRONIC REJECTION

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

☒ Concurrently with submission of a Request for Continued Examination (RCE)


If a fee is deemed required, the Commissioner is hereby authorized to charge such fee to
Deposit Account No. 19-0134 in the name of Novartis.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the
references cited on the attached form(s) PTO-1449.

☒ Copies of the references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application
and indicate that each reference was considered by returning a copy of the initialed PTO 1449
form(s).

Respectfully submitted,



Leslie Fischer
Attorney for Applicant
Reg. No. 58,393

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-9308

Date:

3/12/2010